OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
121260

Astra Industrial Group Company SJSC

PharmaceuticalsVerified

Astra Industrial Group Company SJSC maintains a strong capital structure with a debt-to-equity ratio of 0.08, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.64, suggesting it has sufficient short-term assets to cover its short-term liabilities, though not in excess. However, the company's net cash position is negative after subtracting total debt, which could signal potential liquidity constraints in the near term. In terms of profitability, the company demonstrates a return on equity (ROE) of 22.51% and a return on assets (ROA) of 15.07%, both of which are strong indicators of efficient use of equity and assets to generate profit. These figures suggest that Astra Industrial Group is performing well relative to industry norms, particularly in terms of asset utilization and profitability. The company's operating income of SAR 694.69 million and net income of SAR 666.81 million further support its strong financial performance. The company's revenue is primarily concentrated in the pharmaceuticals segment, with no disclosed geographic breakdown in the provided data. This concentration may expose the company to risks associated with regulatory changes or market shifts within the pharmaceuticals industry. However, the absence of geographic diversification data limits the ability to assess potential regional exposure or concentration risk. Looking ahead, the company is projected to maintain a stable growth trajectory, with no specific numeric deltas provided for the current or next fiscal year. The company's free cash flow of SAR 364.14 million and operating cash flow of SAR 727.65 million indicate a strong ability to fund operations and potentially invest in future growth. The capital expenditure of SAR -152.54 million suggests that the company is not currently investing heavily in new projects or infrastructure, which may indicate a focus on maintaining existing operations rather than expansion. The company's risk profile is characterized by a low dilution potential, with no significant dilution sources identified in the provided data. However, the negative net cash position after subtracting total debt is a key flag that could impact liquidity in the short term. The company's liquidity risk is moderate, and its credit risk is not explicitly quantified, but the strong equity position and low debt levels suggest a relatively stable credit profile. Recent events and filings do not provide specific details on the company's strategic direction or major developments. Analysts have provided a mean price target of SAR 161.09, with a median price target of SAR 161.09, indicating a consensus view of moderate growth potential. The mean recommendation of 3.00 suggests a neutral stance, with no strong buy or buy ratings, and two hold ratings, indicating a cautious outlook from analysts.

30-day price · 1212-11.50 (-8.0%)
Low$131.60High$149.70Close$132.00As of22 May, 00:00 UTC
Profile
CompanyAstra Industrial Group Company SJSC
Ticker1212.SE
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Astra Industrial Group Company SJSC is a pharmaceuticals company that develops, produces, and distributes a range of pharmaceutical products, primarily generating revenue through the sale of these products to healthcare providers and consumers.

Classification. The company is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.92.

Astra Industrial Group Company SJSC maintains a strong capital structure with a debt-to-equity ratio of 0.08, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.64, suggesting it has sufficient short-term assets to cover its short-term liabilities, though not in excess. However, the company's net cash position is negative after subtracting total debt, which could signal potential liquidity constraints in the near term. In terms of profitability, the company demonstrates a return on equity (ROE) of 22.51% and a return on assets (ROA) of 15.07%, both of which are strong indicators of efficient use of equity and assets to generate profit. These figures suggest that Astra Industrial Group is performing well relative to industry norms, particularly in terms of asset utilization and profitability. The company's operating income of SAR 694.69 million and net income of SAR 666.81 million further support its strong financial performance. The company's revenue is primarily concentrated in the pharmaceuticals segment, with no disclosed geographic breakdown in the provided data. This concentration may expose the company to risks associated with regulatory changes or market shifts within the pharmaceuticals industry. However, the absence of geographic diversification data limits the ability to assess potential regional exposure or concentration risk. Looking ahead, the company is projected to maintain a stable growth trajectory, with no specific numeric deltas provided for the current or next fiscal year. The company's free cash flow of SAR 364.14 million and operating cash flow of SAR 727.65 million indicate a strong ability to fund operations and potentially invest in future growth. The capital expenditure of SAR -152.54 million suggests that the company is not currently investing heavily in new projects or infrastructure, which may indicate a focus on maintaining existing operations rather than expansion. The company's risk profile is characterized by a low dilution potential, with no significant dilution sources identified in the provided data. However, the negative net cash position after subtracting total debt is a key flag that could impact liquidity in the short term. The company's liquidity risk is moderate, and its credit risk is not explicitly quantified, but the strong equity position and low debt levels suggest a relatively stable credit profile. Recent events and filings do not provide specific details on the company's strategic direction or major developments. Analysts have provided a mean price target of SAR 161.09, with a median price target of SAR 161.09, indicating a consensus view of moderate growth potential. The mean recommendation of 3.00 suggests a neutral stance, with no strong buy or buy ratings, and two hold ratings, indicating a cautious outlook from analysts.
Key takeaways
  • Astra Industrial Group Company SJSC has a strong return on equity (22.51%) and return on assets (15.07%), indicating efficient use of capital and assets.
  • The company's debt-to-equity ratio of 0.08 suggests a conservative capital structure with minimal reliance on debt.
  • The company's liquidity position is moderate, with a current ratio of 1.64, but a negative net cash position after subtracting total debt raises some concerns.
  • Analysts have provided a neutral outlook, with a mean price target of SAR 161.09 and a mean recommendation of 3.00 (hold).
  • The company's revenue is primarily concentrated in the pharmaceuticals segment, with no disclosed geographic diversification.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencySAR
Revenue$3.07B
Gross profit$1.41B
Operating income$694.7M
Net income$666.8M
R&D
SG&A
D&A
SBC
Operating cash flow$727.7M
CapEx-$152.5M
Free cash flow$364.1M
Total assets$4.42B
Total liabilities$1.46B
Total equity$2.96B
Cash & equivalents$6.5M
Long-term debt$232.9M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$2.96B
Net cash-$226.3M
Current ratio1.6
Debt/Equity0.1
ROA15.1%
ROE22.5%
Cash conversion1.1%
CapEx/Revenue-5.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 1 companies
Metric1212Activity
Op margin22.6%-2.9% medp25 -218.9% · p75 9.6%top quartile
Net margin21.7%28.2% medp25 28.2% · p75 28.2%bottom quartile
Gross margin46.0%47.8% medp25 27.6% · p75 68.9%below median
CapEx / revenue-5.0%6.6% medp25 6.6% · p75 6.6%bottom quartile
Debt / equity8.0%271.5% medp25 271.5% · p75 271.5%bottom quartile
Observations
IR observations
Mean price target161.09 SAR
Median price target161.09 SAR
High price target164.00 SAR
Low price target158.18 SAR
Mean recommendation3.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count0.00
Hold count2.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate9.29 SAR
Last actual EPS8.34 SAR
Source: analysis-pipeline (hybrid)Generated: 2026-05-20 15:18 UTCJob: 95c9c3a8